Symbicort Usage in Asthma Treatment and Impact of a New Therapeutic Strategy on Compliance and Asthma Control in France
Completed
- Conditions
- Asthma
- Registration Number
- NCT00812357
- Lead Sponsor
- AstraZeneca
- Brief Summary
Descriptive pharmacoepidemiological study on the use of Symbicort Turbuhaler in the treatment of asthma in France and impact of a new therapeutic strategy on the compliance and control of asthma
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 579
Inclusion Criteria
- Asthmatic patients treated for this disease with Symbicort Turbuhaler
- Patients monitored for asthma by the doctor for at least 12 months
- Patients seen in outpatient care at the baseline visit
- Patients agreeing to participate in the study
Exclusion Criteria
- Patients with any chronic lower respiratory disease other than asthma
- Patients receiving anti-IgE agents in the last 4 months
- Patients receiving desensitisation treatment outside of the maintenance phase
- Patients deemed to be unable to respond to the study for linguistic or cognitive reasons
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of compliance with treatment 3 months Level of control of the asthma 3 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Research Site
🇫🇷Le Chesnay, Yvelines, France